Atnahs purchases the rights to hypertension medicines from Astra Zeneca.

Atnahs Pharma (AP) has agreed to purchase the global trade rights to several hypertension medicines from Astra Zeneca (AZ) – including Tenormin, Inderal, Zestril, Tenoretic and Zestoretic. Both India and the United States will be excluded from the previously divested agreement and will be retained by AZ in Japan. During the transition period, AZ will continue supplying and distributing the drugs to Atnahs.

BioPharmaceuticals’ Executive Vice President, Ruud Dobber, stated: “These are important established medicines and the divestment to Atnahs ensures they will continue to be available to patients. This transaction supports our strategy to realise value from our portfolio of noncore mature brands, enabling further investment in new medicines.”